SECOND DAY
Thursday September 28th
8.30-10.00 Session I: DNA DAMAGE RESPONSE
8.30-9.00: Exploiting self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress,
Dr Claus Sørensen, University of Copenhagen, D
9.00-9.30: Chromosomal instability-induced inflammation: a catch 22 for cancer cells,
Dr Floris Foijer, University of Groningen, NL
9.30-10.00: A new role of altered R-loop homeostasis in radiation-induced tumor immunogenicity,
Pr Sandra Demaria, Weill Cornell Medicine, USA
10.00-10.30 Coffee break
10.30-12.30 Session II: MYELOID CELLS
10.30-11.00: Myeloid cells in cancer,
Dr Mikael Pittet, University of Geneva, SW
11.00-11.30: Neutrophils in lung cancer: modulators of tumor growth and therapy response,
Dr Etienne Meylan, ULB, B
11.30-12.00: Local and abscopal responses of small-cell lung cancer to radiation therapy,
Pr Julien Sage, Stanford University, USA
12.00-12.30: Enhancing phagocytosis to magnify radiotherapy-induced in situ tumor vaccination,
Dr Rodney Cheng-En Hsieh, Chang Gung Memorial Hospital, Taiwan
12.30-13.30 Lunch break and exhibition
14.00-16.00: Session III: RT DOSE AND MODALITIES
14.00-14.30: Spatially fractionated FLASH radiotherapy modulates the antitumor immune response,
Dr Cristian Fernandez-Palomo, University of Bern, SW
14.30-15.00: Radiotherapy with carbon ions plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model,
Dr Stefan Eichmuller, DKFZ Heidelberg, G
15.00-15.30: Revisiting the radiobiology of targeted alpha therapy,
Dr Jean-Pierre Pouget, Institut de Recherche en Cancérologie de Montpellier, FR
15.30-16.00: Radiotherapy in the context of multimodality treatment for oligometastatic disease,
Dr Mathias Guckenberger, University of Zurich, SW
16.00-16.30 coffee break
16.30-18.00 Session IV: IMMUNOSUPPRESSION
16.30-17.00: IL-1, CAFs and rectal cancer,
Dr Florian Greten, Frankfurt University, G
17.00-17.30: Mapping of stromal heterogeneity and plasticity in breast cancer,
Dr Fatima Mechta-Grigoriou, Institut Curie, FR
Keynote Presentation
17.30-18.15: Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity,
Pr Ralph Weichselbaum, Chicago University, USA
